SNSW(SH:688117) Xin Lang Zheng Quan·2025-08-27 02:13Core Viewpoint - Shengnuo Bio experienced a decline of 3.35% in stock price on August 26, with a trading volume of 271 million yuan, indicating market volatility and investor sentiment [1] Financing Summary - On August 26, Shengnuo Bio had a financing buy-in amount of 39.54 million yuan and a financing repayment of 35.05 million yuan, resulting in a net financing buy of 4.49 million yuan [1] - The total financing and securities balance for Shengnuo Bio reached 516 million yuan, accounting for 7.73% of its circulating market value, which is above the 90th percentile of the past year [1] - The company had no short selling activity on August 26, with a short selling balance of 0.00 yuan, indicating a lack of bearish sentiment [1] Business Overview - Shengnuo Bio, established on July 23, 2001, and listed on June 3, 2021, is located in Chengdu, Sichuan Province [1] - The company's main business includes peptide innovative drug CDMO services, self-developed and sold peptide raw materials and formulations, custom production services for peptide products, and technology transfer services for peptide drug production [1] - The revenue composition of Shengnuo Bio is as follows: raw materials 55.95%, formulations 25.10%, pharmaceutical research 12.43%, custom production 5.31%, other 1.20%, and contract processing 0.01% [1] Financial Performance - As of June 30, the number of shareholders for Shengnuo Bio reached 11,100, an increase of 50.98% compared to the previous period, while the average circulating shares per person decreased by 7.27% to 14,136 shares [2] - For the first half of 2025, Shengnuo Bio reported a revenue of 338 million yuan, representing a year-on-year growth of 69.69%, and a net profit attributable to shareholders of 88.96 million yuan, reflecting a significant increase of 308.29% [2] Dividend Information - Since its A-share listing, Shengnuo Bio has distributed a total of 82.14 million yuan in dividends, with 58.14 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, several institutions exited the top ten circulating shareholders of Shengnuo Bio, including Yuanxin Yongfeng Ju You A, China Merchants Pharmaceutical Health Industry Stock, and Huaan Manufacturing Upgrade One-Year Holding Mixed A [3]